| Date Filed | Type | Description |
| 10/02/2023 |
8-K
| Cost Associated with Exit or Disposal Activities, Material Impairments, Departure of Directors or Certain Officers; Election ... |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/25/2023 |
8-K
| Quarterly results |
| 07/19/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 07/07/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/03/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events ... |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/05/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/26/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/22/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/14/2023 |
SC 13G/A
| 683 Capital Management, LLC reports a 4.5% stake in SQZ Biotechnologies Company |
| 02/14/2023 |
SC 13G/A
| AMERICAN INTERNATIONAL GROUP, INC. reports a 8.5% stake in SQZ Biotechnologies Company |
| 02/14/2023 |
SC 13G/A
| NanoDimension II Management Ltd reports a 4.9% stake in SQZ biotechnologies company |
| 01/18/2023 |
8-K
| Quarterly results |
| 12/06/2022 |
8-K
| Quarterly results |
| 11/30/2022 |
8-K
| Quarterly results |
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 09/06/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"SQZ Biotechnologies Announces Leadership Transition Chief Scientific Officer, Howard Bernstein, M.D., Ph.D., to Become Member of the Company’s Board of Directors, Effective October 31, 2022 CSO Responsibilities to be Shared Among Ipsita Roymoulik, Ph.D., Scott Loughhead, Ph.D., and Maisam Dadgar as Senior Leaders of Chemistry, Manufacturing and Controls; Translational Research; and Engineering WATERTOWN, Mass., September 6, 2022 –" |
|
| 08/04/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/11/2022 |
8-K
| Quarterly results |
| 06/16/2022 |
8-K
| Quarterly results |
| 05/31/2022 |
8-K
| Quarterly results |
| 05/19/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 04/26/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/26/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/16/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 02/14/2022 |
SC 13G/A
| AMERICAN INTERNATIONAL GROUP, INC. reports a 9% stake in SQZ Biotechnologies Company |
| 02/14/2022 |
SC 13G/A
| Temasek Holdings Ltd reports a 9.8% stake in SQZ Biotechnologies Company |
| 02/11/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/11/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 02/10/2022 |
SC 13G/A
| NanoDimension II Management Ltd reports a 5.1% stake in SQZ biotechnologies company |
| 02/09/2022 |
SC 13G/A
| BlackRock Inc. reports a 5% stake in SQZ BIOTECHNOLOGIES CO |
|